Quick Answer
Anebulo Pharmaceuticals, Inc. reported R&D Expense of $4.30 million for fiscal year 2025.
Anebulo Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.30M | +21.2% |
| 2024 | $3.55M | -36.6% |
| 2023 | $5.60M | +89.1% |
| 2022 | $2.96M | +30.5% |
| 2021 | $2.27M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $1.16M | -4.6% | +43.8% |
| September 30, 2025 | $810.0K | -38.4% | +26.9% |
| March 31, 2025 | $638.3K | -14.7% | -47.7% |
| December 31, 2024 | $1.22M | +14.9% | -7.2% |
| September 30, 2024 | $1.31M | +3.5% | +75.7% |
| March 31, 2024 | $748.3K | -31.3% | -29.6% |
| December 31, 2023 | $1.06M | -43.2% | -16.3% |
| September 30, 2023 | $1.27M | +3.8% | +16.6% |
- Anebulo Pharmaceuticals, Inc. showed an increase of +21.2% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, Anebulo Pharmaceuticals, Inc.’s r&d expense has grown by 89.4% (from $2.27 million to $4.30 million).
- The most recent figure is from Anebulo Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: